PET/CT in the Evaluation of Neuroblastoma

Susan E Sharp; Michael J Gelfand; Barry L Shulkin

doi:10.1016/j.cpet.2009.03.006

PET/CT in the Evaluation of Neuroblastoma

PET Clin. 2008 Oct;3(4):551-61. doi: 10.1016/j.cpet.2009.03.006. Epub 2009 Jul 25.

Authors

Susan E Sharp¹, Michael J Gelfand¹, Barry L Shulkin²

Affiliations

¹ Department of Radiology, University of Cincinnati, ML 0761, 234 Goodman Street, Cincinnati, OH 45219, USA; Section of Nuclear Medicine, Department of Radiology, Cincinnati Children's Hospital Medical Center, MLC 5031, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA.
² Nuclear Medicine Division, Department of Radiological Sciences, MS 220, Room I-3128, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678, USA. Electronic address: barry.shulkin@stjude.org.

PMID: 27156819
DOI: 10.1016/j.cpet.2009.03.006

Abstract

I-123-metaiodobenzylguanidine (MIBG) is the most commonly used functional imaging agent in patients with neuroblastoma, but use of [F-18]- FDG PET is increasing. MIBG is useful for defining the extent of disease at diagnosis, following response to treatment, and localizing residual and recurrent disease. In early-stage disease, FDG is often better concentrated in tumor sites than MIBG. In all stages, disease extent in the chest, abdomen, and pelvis and local metastases may be better delineated by FDG. In advanced-stage disease, MIBG is superior for following the treatment response of metastatic tumor in the marrow and bone. Several C-11- and F-18-labeled tracers may be equal to or superior to I-123-MIBG if supply problems can be resolved.

Keywords: FDG; MIBG; Neuroblastoma; PET; PET/CT.

Publication types

Review